Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Increases By 467.7%

Roche Holding AG (OTCMKTS:RHHBY) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 11,741,100 shares, a growth of 467.7% from the February 13th total of 2,068,200 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 9,269,800 shares, the short-interest ratio is presently 1.3 days.

Analyst Upgrades and Downgrades

RHHBY has been the subject of several research analyst reports. Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Morgan Stanley began coverage on Roche in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, UBS Group raised shares of Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Roche Trading Down 2.5 %

Roche stock traded down $1.06 during trading hours on Wednesday, hitting $42.00. 1,863,188 shares of the stock were exchanged, compared to its average volume of 3,002,713. Roche has a 12 month low of $29.20 and a 12 month high of $43.96. The business’s 50-day moving average is $39.31 and its two-hundred day moving average is $38.48. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97.

Institutional Investors Weigh In On Roche

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group acquired a new position in Roche in the third quarter worth $40,000. IHT Wealth Management LLC acquired a new position in Roche during the 3rd quarter worth about $236,000. Verity Asset Management Inc. increased its position in Roche by 26.8% in the 4th quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock valued at $280,000 after acquiring an additional 1,697 shares in the last quarter. Canopy Partners LLC raised its stake in shares of Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after acquiring an additional 344 shares during the last quarter. Finally, HighPoint Advisor Group LLC lifted its position in shares of Roche by 2.8% during the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock worth $387,000 after purchasing an additional 304 shares in the last quarter.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.